https://doi.org/10.4081/cardio.2024.44
To clip or not to clip moderate-to-severe functional mitral regurgitation in patients with heart failure?
Published: November 5, 2024
Abstract Views: 2701
PDF: 650
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Functional mitral regurgitation (FMR) is associated with a poor prognosis, with one-year mortality rates ranging from 15% to 40%.
1. Vajapey R, Kwon D. Guide to functional mitral regurgitation: a contemporary review. Cardiovasc Diagn Ther 2021;11:781-92.
DOI: https://doi.org/10.21037/cdt-20-277
2. van der Bijl P, Khidir M, Ajmone Marsan N, et al. Effect of functional mitral regurgitation on outcome in patients receiving cardiac resynchronization therapy for heart failure. Am J Cardiol 2019;123:7583.
DOI: https://doi.org/10.1016/j.amjcard.2018.09.020
3. Anker SD, Friede T, von Bardeleben RS, et al. Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials. Eur J Heart Fail 2024; 26:160815.
DOI: https://doi.org/10.1002/ejhf.3286
4. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018;379:2307-18.
DOI: https://doi.org/10.1056/NEJMoa1806640
5. Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med 2018;379:2297-306.
DOI: https://doi.org/10.1056/NEJMoa1805374
6. Pibarot P, Delgado V, Bax JJ. MITRA-FR vs. COAPT: lessons from two trials with diametrically opposed results. Eur Heart J Cardiovasc Imaging 2019;20:620-4.
DOI: https://doi.org/10.1093/ehjci/jez073
7. Grayburn PA, Chandrashekhar YS. Functional Mitral Regurgitation: More Questions Than Answers. JACC Cardiovasc Imaging 2021;14:7114.
DOI: https://doi.org/10.1016/j.jcmg.2021.03.001
8. Anker SD, Friede T, von Bardeleben RS, et al. Randomized investigation of the MitraClip device in heart failure: Design and rationale of the RESHAPE-HF2 trial design. Eur J Heart Fail 2024;26:98493.
DOI: https://doi.org/10.1002/ejhf.3247
9. von Bardeleben RS, Khan MS, Geyer M, et al. Baseline echocardiographic characteristics of patients enrolled in the randomized investigation of MitraClip device in heart failure (RESHAPE HF-2) trial: comparison with COAPT and Mitra-FR. Glob Cardiol 2024;2:40.
DOI: https://doi.org/10.4081/cardio.2024.40
10. Anker SD, Butler J, Talha KM, Friede T. Using multiple primary endpoints in clinical trials with a focus on heart failure. Glob Cardiol 2024;2:33.
DOI: https://doi.org/10.4081/cardio.2024.33
How to Cite
Khan, M. S., Butler, J., Friede, T., Ponikowski, P., & Anker, S. D. (2024). To clip or not to clip moderate-to-severe functional mitral regurgitation in patients with heart failure?. Global Cardiology, 2(3). https://doi.org/10.4081/cardio.2024.44
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Stefan Peters, Encasement of the left anterior descending coronary artery: association with Takotsubo syndrome, and diagnostic and therapeutic options , Global Cardiology: Vol. 1 No. 1 (2023)
- Ahmad Shabbir, Laiba Yumn, Esha Khan, Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy , Global Cardiology: Vol. 2 No. 3 (2024)
- Elias Tassoulas, Dimitrios Tasoulas, Christos Papaconstantinou, Ioannis Chlorogiannis, Prognostic factors and outcome in patients submitted into coronary artery bypass surgery with total arterial myocardial revascularization , Global Cardiology: Vol. 2 No. 4 (2024)
- Andrew J.S. Coats, Global Cardiology issue highlights , Global Cardiology: Vol. 2 No. 2 (2024)
You may also start an advanced similarity search for this article.
